10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
UK biotech services firm Abzena has signed an agreement to support an integrated CMC program with Lipum, a Sweden-based company developing treatments for chronic inflammatory diseases. 20 March 2019
Germany’s Merck KGaA and US pharma giant Pfizer have discontinued the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of Bavencio (avelumab) in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib. 20 March 2019
The much-hyped cancer drug Venclexta (venetoclax) has already been approved to treat certain patients with chronic lymphocytic leukemia and acute myeloid leukemia, but it is unlikely to become a multiple myeloma treatment any time soon. 19 March 2019
Japanese drugmaker Ono Pharmaceutical has signed a drug discovery research collaboration with twoXAR, a USA-based artificial intelligence (AI)-driven biopharmaceutical company, to jointly discover and develop novel, efficacious treatments to address unmet medical needs in a specific neurological disease. 19 March 2019
Just a week after a Tecentriq (atezolizumab) combination was the first cancer immunotherapy regimen to be approved for breast cancer in the USA, the Roche drug has achieved another milestone. 19 March 2019
Darmstadt, Germany-based Merck KGaA has entered into a strategic alliance with Chinese biotech company GenScript, based around plasmid and viral vector manufacturing. 19 March 2019
South Korean RNAi therapeutics developer OliX Pharmaceuticals has signed a license and collaboration agreement with Théa Open Innovation, a sister company of France-headquartered Laboratoires Théa, to develop and commercialize OLX301A, a novel treatment for age-related macular degeneration (AMD). 19 March 2019
Hamburg-based drug development firm Evotec has formed a new partnership with the Global Antibiotic Research and Development Partnership (GARDP) to tackle the growing threat of antimicrobial resistance. 19 March 2019
UK vaccine R&D company ImmunoBiology (ImmBio) has recently signed a licensing agreement with LIBP (Lanzhou Institute of Biological Product), a subsidiary company of China National Biotec Group (CNBG). 18 March 2019
Roche majority-owned Chugai has filed a new drug application (NDA) to Japan’s Ministry of Health, Labor and Welfare for entrectinib for the treatment of ROS1 fusion-positive non-small cell lung cancer (NSCLC). 18 March 2019
Shares of Spectrum Pharmaceuticals dropped 8% in pre-market trading on Friday, after it revealed a further disappointment in the development of its lead product candidate Rolontis (eflapegrastim). 18 March 2019
The European Commission (EC) has approved a new indication for Praluent (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease (ASCVD) by lowering low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correction of other risk factors. 18 March 2019
Nicox and China’s Ocumension Therapeutics have entered into an exclusive license agreement for the development and commercialization of Nicox' product Zerviate 15 March 2019
The European Medicines Agency has granted approval for Roche to market MabThera (rituximab) against a rare condition, pemphigus vulgaris (PV). 15 March 2019
Across the USA, insurers denied access to the new cholesterol-lowering medications known as a PCSK9 inhibitors, for as many as one in three high-risk heart patients in 2018. 14 March 2019
New Jersey, USA-based Merck & Co has picked up another approval in Europe for Keytruda (pembrolizumab), in combination with chemo, for the first-line treatment of squamous non-small cell lung cancer (NSCLC). 14 March 2019